FOXO4-DRI
An experimental senolytic peptide; cell research is not human rejuvenation.
Investigational / no FDA-approved-treatment claim
An experimental senolytic peptide; cell research is not human rejuvenation.
Reviewed October 10, 2026. Product and route distinctions stay attached to the source; this is not a treatment recommendation.
Purported uses, not established benefits
Proponents describe FOXO4-DRI as a way to remove senescent cells and potentially support tissue health or healthy aging.
The cited study concerns human cartilage cells expanded in a laboratory, not people receiving treatment. Selective cell effects do not demonstrate longer life or clinical joint repair.
Evidence and source limits
The source linked here describes research or investigational use. It does not establish an FDA-approved indication for this compound or for a research-chemical product. A claimed use is not an established benefit.
Product identity, purity, route, safety and suitability remain separate questions. Research-purpose-only labeling does not authorize human use. This note provides no dosing, preparation or purchase guidance.
Interpretation is limited to the source linked above. Educational source review, not independent medical review. No dosing, preparation instructions, seller links or treatment endorsement.